Latest News

03 Dec 2015 FDA Approves Elotuzumab for the Treatment of Multiple Myeloma Haematologic malignancies - Anticancer agents & Biologic therapy
02 Dec 2015 Lung Adenocarcinoma With HER2 Mutations Personalised medicine - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
01 Dec 2015 Latest Lung Cancer E-Learning Now Online!
01 Dec 2015 NHS England and NICE Have Begun a Consultation on a New Cancer Drugs Fund Bioethics, legal and economic issues
30 Nov 2015 FDA Approves Nivolumab as a Single Agent for Previously Untreated BRAF Wild-Type Advanced Melanoma Melanoma - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
27 Nov 2015 FDA Approves Necitumumab to Treat Advanced Squamous NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy
26 Nov 2015 European Medicines Agency Recommends Granting a Marketing Authorisation for Pemetrexed Accord and Pemetrexed Actavis Lung and other thoracic tumours - Anticancer agents & Biologic therapy
25 Nov 2015 FDA Approves Ixazomib, New Oral Proteasome Inhibitor for Treatment of Multiple Myeloma Haematologic malignancies - Anticancer agents & Biologic therapy
24 Nov 2015 FDA Approves Nivolumab for the Treatment of Advanced Renal Cell Cancer Genitourinary cancers - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
24 Nov 2015 European Medicines Agency Recommends Granting a Marketing Authorisation for Asparaginase and Pegaspargase Haematologic malignancies - Anticancer agents & Biologic therapy
CME Tests for Handbooks
19 Nov 2015 FDA Approves Daratumumab for Patients With Previously Treated Multiple Myeloma Haematologic malignancies
18 Nov 2015 Dabrafenib Produces Rapid Shrinkage of Recurrent, BRAF-mutant Papillary Craniopharyngioma Personalised medicine - Endocrine cancers - Anticancer agents & Biologic therapy
17 Nov 2015 Distinct Evolutionary Trajectories Reported for Different Melanoma Subtypes Pathology/Molecular biology - Melanoma